The role of MALAT1 and UCA1 long non‐coding RNAs on the prognosis of patients with glioblastoma: A systematic review and meta‐analysis

Le résumé fourni par la source

Abstract Glioblastoma multiforme (GBM) is a common central nervous system malignancy with poor survival despite new treatments. Although some evidence demonstrated the prognostic effects of metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) and urothelial carcinoma associated 1 (UCA1) long non‐coding RNAs (lncRNAs) in patients with GBM, a comprehensive study has not yet evaluated the clinical importance of these lncRNAs. Hence, this review aimed to predict the significance of expressions of MALAT and UCA1 lncRNAs in patients with GBM. Using proper keywords, a thorough literature search was performed via databases, including PubMed, Web of Knowledge, Scopus, and EMBASE until December 2024. The relationship between lncRNA expressions and overall survival (OS) in patients with GBM was assessed using hazard ratios (HR) and confidence intervals (95% CI), and the fixed and random effects models were used to estimate the pooled effect size. Also, the Newcastle‐Ottawa Quality Assessment Scale was used as an appraisal tool. Among 1553 initially founded records, 13 studies were enrolled in the final analysis, consisting of 915 and 257 samples in the MALAT1 and UCA1 groups, respectively. Compared to the patients with low expression, those with high expression of MALAT1 had a mortality risk of 80% (HR = 1.8, 95% CI = [1.39, 2.33], p = .001). Additionally, the impact of UCA1 expression on patient prognosis indicated that lower OS among patients was correlated with high expression of UCA1; however, the meta‐analysis was not performed for UCA1 due to a lack of adequate studies. According to our findings, high expression of MALAT1 was correlated with poor prognosis in patients with GBM.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.